Register Login

Xenon Pharmaceuticals Inc (XENE)

  • Event
  • June 21, 2022, 11:03 UTC

(10% Negative) XENON PHARMACEUTICALS INC. (XENE) Announces Delay in patients Development Timeline Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 8:23 a.m.

    📋 XENON PHARMACEUTICALS INC. (XENE) - Clinical Trial Update

    Filing Date: 2022-06-21

    Accepted: 2022-06-21 07:03:03

    Event Type: Clinical Trial Update

    Event Details:

    Xenon Pharmaceuticals Inc (XENE) Announces Clinical Trial Update Xenon Pharmaceuticals Inc (XENE) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: patients, program
    • Clinical Stage: Phase 3, Phase 3 program
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: BURNABY

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Xenon Pharmaceuticals Inc
    • CIK: 0001582313
    • Ticker Symbol: XENE
    • Period End Date: 2022-06-21
    • Document Type: 8-K

Search

News categories